evolocumab
ApprovedCompleted 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Homozygous Familial Hypercholesterolemia HoFH
Conditions
Homozygous Familial Hypercholesterolemia HoFH
Trial Timeline
Aug 4, 2018 → Nov 27, 2019
NCT ID
NCT03403374About evolocumab
evolocumab is a approved stage product being developed by Amgen for Homozygous Familial Hypercholesterolemia HoFH. The current trial status is completed. This product is registered under clinical trial identifier NCT03403374. Target conditions include Homozygous Familial Hypercholesterolemia HoFH.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (17)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06140095 | Phase 1 | UNKNOWN |
| NCT04539223 | Approved | UNKNOWN |
| NCT03944577 | Phase 2 | Completed |
| NCT03331666 | Approved | Terminated |
| NCT03403374 | Approved | Completed |
| NCT03096288 | Approved | Completed |
| NCT03080935 | Phase 3 | Terminated |
| NCT02957604 | Pre-clinical | Terminated |
| NCT02624869 | Phase 3 | Completed |
| NCT02867813 | Phase 3 | Completed |
| NCT02585895 | Phase 3 | Completed |
| NCT02304484 | Phase 3 | Completed |
| NCT02275156 | Phase 1 | Completed |
| NCT01652703 | Phase 2 | Completed |
| NCT01624142 | Phase 2/3 | Completed |
| NCT01439880 | Phase 2 | Completed |
| NCT01380730 | Phase 2 | Completed |
Competing Products
20 competing products in Homozygous Familial Hypercholesterolemia HoFH